The use of gabapentin in the treatment of keratoconus

The use of gabapentin in the management of postoperative pain in Crosslinking

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-23r5mc

Enrollment

Unknown

Registered

2020-09-22

Start date

2018-06-10

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Twelve participants with progressive keratoconus who underwent Crosslinking were selected, of both sexes, aged 10 to 40 years. Thirty minutes before the start of the procedure, 1% pilocarpine eye drop

Procedure/surgery

E02.186.450

Eligibility

Age

10 Years to 40 Years

Inclusion criteria

Inclusion criteria: Twelve participants with progressive keratoconus who underwent Crosslinking were selected, of both sexes, aged 10 to 40 years.

Exclusion criteria

Exclusion criteria: Intellectual inability to answer the questionnaire applied in the postoperative period. Allergy to the drug Gabapentin.

Design outcomes

Primary

Measure	Time frame
expected outcome 1: Gabapentin is expected to be effective in postoperative pain control after corneal CXL (fast - 10 minutes) compared to placebo.;Outcome presented 1: It was observed that gabapentin did not demonstrate efficacy in pain control in the postoperative period after corneal CXL (fast - 10 minutes) compared to placebo.	—

Secondary

Measure	Time frame
Secondary outcomes are not expected.	—

Countries

Brazil

Contacts

Public ContactElcio Bonamigo

Universidade do Oeste de Santa Catarina

elcio.bonamigo@unoesc.edu.br554935220717

Outcome results

None listed

Source: REBEC (via WHO ICTRP)